Dyslipidemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Dyslipidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dyslipidemia - The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects - The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dyslipidemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dyslipidemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Dyslipidemia Overview 12 Therapeutics Development 13 Pipeline Products for Dyslipidemia - Overview 13 Pipeline Products for Dyslipidemia - Comparative Analysis 14 Dyslipidemia - Therapeutics under Development by Companies 15 Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 21 Dyslipidemia - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Dyslipidemia - Products under Development by Companies 26 Dyslipidemia - Products under Investigation by Universities/Institutes 34 Dyslipidemia - Companies Involved in Therapeutics Development 35 Acasti Pharma Inc. 35 Allergan Plc 36 Alnylam Pharmaceuticals, Inc. 37 Amgen Inc. 38 Arbutus Biopharma Corporation 39 Arisaph Pharmaceuticals, Inc. 40 Astellas Pharma Inc. 41 AstraZeneca Plc 42 AtheroNova Inc. 43 BASF SE 44 BCWorld Pharm Co. Ltd. 45 Cadila Pharmaceuticals Ltd. 46 Cardax Pharmaceuticals, Inc. 47 Catabasis Pharmaceuticals, Inc. 48 Cerenis Therapeutics Holding SA 49 Chong Kun Dang Pharmaceutical Corp. 50 CJ HealthCare Corp. 51 Connexios Life Sciences Pvt. Ltd. 52 CymaBay Therapeutics, Inc. 53 Daewoong Pharmaceutical Co., Ltd. 54 Daiichi Sankyo Company, Limited 55 Debiopharm International S.A. 56 Eli Lilly and Company 57 Esperion Therapeutics, Inc. 58 Genfit SA 59 GlaxoSmithKline Plc 60 HanAll Biopharma Co., Ltd. 61 Hanmi Pharmaceuticals, Co. Ltd. 62 Huons Co., Ltd. 63 Hyundai Pharmaceutical Co., Ltd. 64 Innovent Biologics, Inc. 65 IPCA Laboratories Limited 66 Jeil Pharmaceutical Co., Ltd. 67 Jenrin Discovery, Inc. 68 JW Pharmaceutical Corporation 69 Kissei Pharmaceutical Co., Ltd. 70 Kotobuki Pharmaceutical Co., Ltd. 71 Kowa Company, Ltd. 72 Kymab Limited 73 LG Life Science LTD. 74 Lipicard Technologies Limited 75 Lotus Pharmaceutical Co., Ltd. 76 Matinas BioPharma Holdings, Inc. 77 Merck & Co., Inc. 78 Nimbus Therapeutics, LLC 79 Nippon Chemiphar Co., Ltd. 80 Pfizer Inc. 81 Pharmena SA 82 Prometheon Pharma, LLC 83 Protalix BioTherapeutics, Inc. 84 Regeneron Pharmaceuticals, Inc. 85 Sancilio & Company, Inc. 86 Takeda Pharmaceutical Company Limited 87 Thetis Pharmaceuticals LLC 88 Torrent Pharmaceuticals Limited 89 Viking Therapeutics, Inc. 90 Yuhan Corporation 91 Zydus Cadila Healthcare Limited 92 Dyslipidemia - Therapeutics Assessment 93 Assessment by Monotherapy Products 93 Assessment by Combination Products 94 Assessment by Target 95 Assessment by Mechanism of Action 100 Assessment by Route of Administration 103 Assessment by Molecule Type 105 Drug Profiles 107 (amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 107 (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 108 (atorvastatin calcium + choline fenofibrate) - Drug Profile 109 (atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 110 (atorvastatin calcium + losartan potassium) - Drug Profile 111 (atorvastatin calcium + metformin hydrochloride) XR - Drug Profile 112 (candesartan + rosuvastatin calcium) - Drug Profile 113 (ezetimibe + rosuvastatin calcium) - Drug Profile 114 (gemigliptin + rosuvastatin calcium) - Drug Profile 115 (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 116 (pitavastatin + valsartan) - Drug Profile 117 4655-K09 - Drug Profile 118 AEM-28 - Drug Profile 119 AEM-2802 - Drug Profile 120 AEM-2814 - Drug Profile 121 AHRO-001 - Drug Profile 122 ALN-AC3 - Drug Profile 124 ALN-ANG - Drug Profile 125 AMG-899 - Drug Profile 126 anacetrapib - Drug Profile 127 ARI-3037MO - Drug Profile 129 AS-1708727 - Drug Profile 130 AZ-12260493 - Drug Profile 131 BCWPC-001 - Drug Profile 132 bempedoic acid - Drug Profile 133 bezafibrate ER - Drug Profile 136 BH-03004 - Drug Profile 137 BioE-1115 - Drug Profile 138 bococizumab - Drug Profile 139 BSN-272 - Drug Profile 140 C-24 - Drug Profile 141 C-3 - Drug Profile 142 CAT-2000 Series - Drug Profile 143 CAT-2003 - Drug Profile 144 CDR-267F018 - Drug Profile 145 CDX-085 - Drug Profile 146 centatin - Drug Profile 148 CER-209 - Drug Profile 149 CKD-519 - Drug Profile 150 CNX-013B2 - Drug Profile 151 Debio-0930B - Drug Profile 152 DF-461 - Drug Profile 153 DPR-212 - Drug Profile 154 DS-8312 - Drug Profile 155 DS-9001 - Drug Profile 156 DWJ-1330 - Drug Profile 158 DWJ-1351 - Drug Profile 159 elafibranor - Drug Profile 160 etanercept biosimilar - Drug Profile 163 evinacumab - Drug Profile 164 evolocumab - Drug Profile 165 gemcabene calcium - Drug Profile 168 GSK-2041706 - Drug Profile 169 HCP-1105 - Drug Profile 170 HOB-071 - Drug Profile 171 HU-012 - Drug Profile 172 IBI-306 - Drug Profile 173 icosabutate - Drug Profile 174 IONIS-ANGPTL3LRx - Drug Profile 175 ISIS-APOCIIILRx - Drug Profile 176 JD-2000 Series - Drug Profile 177 JD-5000 Series - Drug Profile 178 JD-5006 - Drug Profile 179 JD-5037 - Drug Profile 180 JD-6000 Series - Drug Profile 181 JLP-1302 - Drug Profile 182 JLP-1401 - Drug Profile 183 K-312 - Drug Profile 184 K-877 - Drug Profile 185 KT-6971 - Drug Profile 187 KTA-439 - Drug Profile 188 KY-1020 - Drug Profile 189 leucine + niacin - Drug Profile 190 LP-071 - Drug Profile 191 LT-5421 - Drug Profile 192 LT-5423 - Drug Profile 193 MAT-9001 - Drug Profile 194 MBX-8025 - Drug Profile 195 NC-2400 - Drug Profile 197 ND-630 - Drug Profile 198 ND-654 - Drug Profile 199 NKPL-66 - Drug Profile 201 Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 203 omega-3-carboxylic acids - Drug Profile 204 peroxibrate - Drug Profile 206 PF-06427878 - Drug Profile 207 PF-06815345 - Drug Profile 208 pitavastatin CR - Drug Profile 209 Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 210 Recombinant ApoE4 for Dyslipidemia - Drug Profile 211 REGN-1001 - Drug Profile 212 saroglitazar - Drug Profile 213 SC-401 - Drug Profile 214 Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type-2 diabetes - Drug Profile 215 Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type-2 diabetes - Drug Profile 216 Small Molecule for Hyperlipidemia - Drug Profile 217 Small Molecule for Hypertriglyceridaemia - Drug Profile 218 Small Molecule for Hypertriglyceridemia - Drug Profile 219 Small Molecule for Type-2 diabetes and Hyperlipidemia - Drug Profile 220 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 221 Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 222 Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 223 Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia - Drug Profile 224 Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 225 Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile 226 Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity - Drug Profile 227 Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 228 SPX-100 - Drug Profile 229 SPX-8522876 - Drug Profile 230 Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 231 TKMApoC-3 - Drug Profile 233 TP-101 - Drug Profile 234 TP-452 - Drug Profile 235 TRC-210258 - Drug Profile 236 TRIA-662 - Drug Profile 237 VK-0214 - Drug Profile 239 VK-2809 - Drug Profile 240 volanesorsen sodium - Drug Profile 242 YH-22189 - Drug Profile 244 ZLN-005 - Drug Profile 245 ZLN-024 - Drug Profile 246 ZYH-7 - Drug Profile 247 Dyslipidemia - Recent Pipeline Updates 248 Dyslipidemia - Dormant Projects 306 Dyslipidemia - Discontinued Products 322 Dyslipidemia - Product Development Milestones 328 Featured News & Press Releases 328 Appendix 336 Methodology 336 Coverage 336 Secondary Research 336 Primary Research 336 Expert Panel Validation 336 Contact Us 336 Disclaimer 337
List of Tables
Number of Products under Development for Dyslipidemia, H1 2016 21 Number of Products under Development for Dyslipidemia - Comparative Analysis, H1 2016 22 Number of Products under Development by Companies, H1 2016 24 Number of Products under Development by Companies, H1 2016 (Contd..1) 25 Number of Products under Development by Companies, H1 2016 (Contd..2) 26 Number of Products under Development by Companies, H1 2016 (Contd..3) 27 Number of Products under Development by Companies, H1 2016 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Development, H1 2016 32 Comparative Analysis by Unknown Stage Development, H1 2016 33 Products under Development by Companies, H1 2016 34 Products under Development by Companies, H1 2016 (Contd..1) 35 Products under Development by Companies, H1 2016 (Contd..2) 36 Products under Development by Companies, H1 2016 (Contd..3) 37 Products under Development by Companies, H1 2016 (Contd..4) 38 Products under Development by Companies, H1 2016 (Contd..5) 39 Products under Development by Companies, H1 2016 (Contd..6) 40 Products under Development by Companies, H1 2016 (Contd..7) 41 Products under Investigation by Universities/Institutes, H1 2016 42 Dyslipidemia - Pipeline by Acasti Pharma Inc., H1 2016 43 Dyslipidemia - Pipeline by Allergan Plc, H1 2016 44 Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 45 Dyslipidemia - Pipeline by Amgen Inc., H1 2016 46 Dyslipidemia - Pipeline by Arbutus Biopharma Corporation, H1 2016 47 Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016 48 Dyslipidemia - Pipeline by Astellas Pharma Inc., H1 2016 49 Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2016 50 Dyslipidemia - Pipeline by AtheroNova Inc., H1 2016 51 Dyslipidemia - Pipeline by BASF SE, H1 2016 52 Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 53 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2016 54 Dyslipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 55 Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 56 Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 57 Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 58 Dyslipidemia - Pipeline by CJ HealthCare Corp., H1 2016 59 Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 60 Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 61 Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 62 Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 63 Dyslipidemia - Pipeline by Debiopharm International S.A., H1 2016 64 Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2016 65 Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2016 66 Dyslipidemia - Pipeline by Genfit SA, H1 2016 67 Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H1 2016 68 Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 69 Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 70 Dyslipidemia - Pipeline by Huons Co., Ltd., H1 2016 71 Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 72 Dyslipidemia - Pipeline by Innovent Biologics, Inc., H1 2016 73 Dyslipidemia - Pipeline by IPCA Laboratories Limited, H1 2016 74 Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 75 Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H1 2016 76 Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H1 2016 77 Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 78 Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2016 79 Dyslipidemia - Pipeline by Kowa Company, Ltd., H1 2016 80 Dyslipidemia - Pipeline by Kymab Limited, H1 2016 81 Dyslipidemia - Pipeline by LG Life Science LTD., H1 2016 82 Dyslipidemia - Pipeline by Lipicard Technologies Limited, H1 2016 83 Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 84 Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 85 Dyslipidemia - Pipeline by Merck & Co., Inc., H1 2016 86 Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H1 2016 87 Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 88 Dyslipidemia - Pipeline by Pfizer Inc., H1 2016 89 Dyslipidemia - Pipeline by Pharmena SA, H1 2016 90 Dyslipidemia - Pipeline by Prometheon Pharma, LLC, H1 2016 91 Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 92 Dyslipidemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 93 Dyslipidemia - Pipeline by Sancilio & Company, Inc., H1 2016 94 Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 95 Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 96 Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 97 Dyslipidemia - Pipeline by Viking Therapeutics, Inc., H1 2016 98 Dyslipidemia - Pipeline by Yuhan Corporation, H1 2016 99 Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 100 Assessment by Monotherapy Products, H1 2016 101 Assessment by Combination Products, H1 2016 102 Number of Products by Stage and Target, H1 2016 104 Number of Products by Stage and Mechanism of Action, H1 2016 109 Number of Products by Stage and Route of Administration, H1 2016 112 Number of Products by Stage and Molecule Type, H1 2016 114 Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016 256 Dyslipidemia - Dormant Projects, H1 2016 314 Dyslipidemia - Dormant Projects (Contd..1), H1 2016 315 Dyslipidemia - Dormant Projects (Contd..2), H1 2016 316 Dyslipidemia - Dormant Projects (Contd..3), H1 2016 317 Dyslipidemia - Dormant Projects (Contd..4), H1 2016 318 Dyslipidemia - Dormant Projects (Contd..5), H1 2016 319 Dyslipidemia - Dormant Projects (Contd..6), H1 2016 320 Dyslipidemia - Dormant Projects (Contd..7), H1 2016 321 Dyslipidemia - Dormant Projects (Contd..8), H1 2016 322 Dyslipidemia - Dormant Projects (Contd..9), H1 2016 323 Dyslipidemia - Dormant Projects (Contd..10), H1 2016 324 Dyslipidemia - Dormant Projects (Contd..11), H1 2016 325 Dyslipidemia - Dormant Projects (Contd..12), H1 2016 326 Dyslipidemia - Dormant Projects (Contd..13), H1 2016 327 Dyslipidemia - Dormant Projects (Contd..14), H1 2016 328 Dyslipidemia - Dormant Projects (Contd..15), H1 2016 329 Dyslipidemia - Discontinued Products, H1 2016 330 Dyslipidemia - Discontinued Products (Contd..1), H1 2016 331 Dyslipidemia - Discontinued Products (Contd..2), H1 2016 332 Dyslipidemia - Discontinued Products (Contd..3), H1 2016 333 Dyslipidemia - Discontinued Products (Contd..4), H1 2016 334 Dyslipidemia - Discontinued Products (Contd..5), H1 2016 335
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.